High-Tech Healing: What GPs Should Know About Cyberknife Radiation

0.5 CE Credit Hour / Siobhan Haney, VMD, MS, DACVR (RO), MBA

Siobhan Haney, VMD, MS, DACVR (RO), MBA

Siobhan Haney, VMD, MS, DACVR (RO), MBA

Dr. Siobhan Haney is a board-certified veterinary radiation oncologist practicing at BluePearl Pet Hospital and the BluePearl Veterinary CyberKnife Cancer Center in Malvern, Pennsylvania. She specializes in advanced cancer treatments for companion animals, including CyberKnife stereotactic radiation therapy, intensitymodulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), and palliative care. Dr. Haney has lectured nationally and internationally and has contributed to multiple studies on conventional and stereotactic radiation therapies. She completed her residency at Tufts University and earned her veterinary degree from the University of Pennsylvania. She also holds a Master of Science in Biology from Rutgers University and an MBA from Pennsylvania State University. Outside of work, Dr. Haney enjoys organizing, exploring fine art and historic homes, staying active on her Peloton, and spending time with her husband and two children.

Overview:

Cyberknife radiation therapy is revolutionizing cancer treatment in veterinary medicine, offering precision therapy without the need for traditional surgery. This bite-sized session introduces general practitioners to the technology, principles, and clinical applications of Cyberknife therapy. Participants will learn how this non-invasive approach can target tumors with unparalleled accuracy, minimize side effects, and expand treatment options for patients who may not be surgical candidates.

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • Describe the principles and technology behind Cyberknife radiation therapy.
  • Identify cancer types and patient scenarios that may benefit from Cyberknife treatment.
  • Explain the advantages and limitations of Cyberknife compared to traditional surgery and radiation therapy.
  • Integrate Cyberknife treatment considerations into general practice case discussions and referral decisions.
  • Evaluate patient suitability and potential outcomes to guide clinical recommendations.

    This course is RACE-approved for 0.5 continuing education credits hours in jurisdictions that accept RACE-approval.